Curti A.; Ruggeri L.; D'Addio A.; Bontadini A.; Dan E.; Motta M.R.; Trabanelli S.; Giudice V.; Urbani E.; Martinelli G.; Paolini S.; Fruet F.; Isidori A.; Parisi S.; Bandini G.; Baccarani M.; Velardi A.; Lemoli R.M., Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients., «BLOOD», 2011, 118, pp. 3273 - 3279 [Scientific article]
Piccaluga PP; Sabattini E; Bacci F; Agostinelli C; Righi S; Salmi F; Testoni N; Paolini S; Castagnetti F; Martinelli G; Falini B; Pileri SA., Cytoplasmic mutated nucleophosmin (NPM1) in blast crisis of chronic myeloid leukaemia., «LEUKEMIA», 2009, 23, pp. 1370 - 1371 [Scientific article]
Soverini S; Gnani A; Colarossi S; Castagnetti F; Abruzzese E; Paolini S; Merante S; Orlandi E; de Matteis S; Gozzini A; Iacobucci I; Palandri F; Gugliotta G; Papayannidis C; Poerio A; Amabile M; Cilloni D; Rosti G; Baccarani M; Martinelli G., Philadelphia-positive patients who already harbour imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors., «BLOOD», 2009, 114, pp. 2168 - 2171 [Scientific article]
Derenzini E;Paolini S;Martinelli G;Campidelli C;Grazi GL;Calabrese C;Zinzani PL;Baccarani M., Extramedullary myeloid tumour of the stomach and duodenum presenting without acute myeloblastic leukemia: a diagnostic and therapeutic challenge., «LEUKEMIA & LYMPHOMA», 2008, 49, pp. 159 - 162 [Scientific article]
Malagola M; Peli A; Damiani D; Candoni A; Tiribelli M; Martinelli G; Piccaluga PP; Paolini S; De Rosa F; Lauria F; Bocchia M; Gobbi M; Pierri I; Zaccaria A; Zuffa E; Mazza P; Priccolo G; Gugliotta L; Bonini A; Visani G; Skert C; Bergonzi C; Roccaro AM; Filì C; Fanin R; Baccarani M; Russo D., Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 yr treated with induction regimens including fludarabine: retrospective analysis of 224 cases, «EUROPEAN JOURNAL OF HAEMATOLOGY», 2008, 81(5), pp. 354 - 363 [Scientific article]
Palmisano M; Grafone T; Renzulli M; Ottaviani E; Testoni N; Paolini S; Papayannidis C; Baccarani M; Martinelli G, Molecular and chromosomal alterations: new therapies for relapsed acute myeloid leukemia., «HEMATOLOGY», 2008, 13(1), pp. 1 - 12 [Scientific article]
Martinelli G; Rondoni M; Ottaviani E; Paolini S; Baccarani M., Hypereosinophilic syndrome and molecularly targeted therapy., «SEMINARS IN HEMATOLOGY», 2007, 44 (Suppl 2), pp. S4 - S16 [Scientific article]
Piccaluga PP; Rondoni M; Paolini S; Rosti G; Martinelli G; Baccarani M., Imatinib mesylate in the treatment of hematologic malignancies., «EXPERT OPINION ON BIOLOGICAL THERAPY», 2007, 7 (10), pp. 1597 - 1611 [Scientific article]
Piccaluga PP; Ascani S; Agostinelli C; Paolini S; Laterza C; Papayannidis C; Martinelli G; Visani G; Baccarani M; Pileri SA., Myeloid sarcoma of liver: an unusual cause of jaundice. Report of three cases and review of literature, «HISTOPATHOLOGY», 2007, 50(6), pp. 802 - 805 [Scientific article]
Piccaluga PP; Finelli C; Vigna E; Agostinelli C; Bacci F; Paolini S; Papayannidis C; Laterza C; Martinelli G; Pileri SA; Baccarani M., Paraplegia due to a paravertebral extramedullary haemopoiesis in a patient with polycythaemia vera., «JOURNAL OF CLINICAL PATHOLOGY», 2007, 60(5), pp. 581 - 582 [Scientific article]
Soverini S; Colarossi S; Gnani A; Castagnetti F; Rosti G; Bosi C; Paolini S; Rondoni M; Piccaluga PP; Palandri F; Giannoulia P; Marzocchi G; Luatti S; Testoni N; Iacobucci I; Cilloni D; Saglio G; Baccarani M; Martinelli G., Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain, «HAEMATOLOGICA», 2007, 92, pp. 401 - 404 [Scientific article]
Soverini S; Martinelli G; Colarossi S; Gnani A; Rondoni M; Castagnetti F; Paolini S; Rosti G; Baccarani M., Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL, «THE LANCET ONCOLOGY», 2007, 8, pp. 273 - 274 [Scientific article]
Baccarani M; Cilloni D; Rondoni M; Ottaviani E; Messa F; Merante S; Tiribelli M; Buccisano F; Testoni N; Gottardi E; de Vivo A; Giugliano E; Iacobucci I; Paolini S; Soverini S; Rosti G; Rancati F; Astolfi C; Pane F; Saglio G; Martinelli G., The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study., «HAEMATOLOGICA», 2007, 92, pp. 1173 - 1179 [Scientific article]
Piccaluga PP; Paolini S; Martinelli G., Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia., «CANCER», 2007, 110(6), pp. 1178 - 1186 [Scientific article]
Iacobucci I; Saglio G; Rosti G; Testoni N; Pane F; Amabile M; Poerio A; Soverini S; Bassi S; Cilloni D; Bassan R; Breccia M; Lauria F; Izzo B; Merante S; Frassoni F; Paolini S; Montefusco E; Baccarani M; Martinelli G, Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients., «CLINICAL CANCER RESEARCH», 2006, 12, pp. 3037 - 3042 [Scientific article]
